Startup profile · funding coverage
Benchling
R&D cloud platform — the operating system for life science labs.
Stage
growth
Status
private
Coverage
full
Why Benchling is interesting
Benchling is the SaaS system of record for biotech R&D — from a16z seed to $6.1B valuation with Sequoia, Altimeter, and Tiger Global in the syndicate.
Key facts
- Series F (Nov 2021): $100M at $6.1B co-led by Franklin Templeton and Altimeter; Tiger Global, Lone Pine joined (Benchling press)
- Series E (Apr 2021): led by Sequoia at $4B valuation (Bloomberg)
- Product: ELN, molecular biology tools, sample tracking for biotech/pharma R&D (Benchling site)
- Co-investors not in VCT directory: Franklin Templeton, Lone Pine Capital
Investors in our directory
Funds linked from Benchling's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Enterprise SaaS
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Benchling
Funding context and why this company shows up in venture coverage.
Benchling provides a cloud R&D platform for life science labs — electronic lab notebooks, molecular biology design tools, sample tracking, and workflow management for biotech and pharma research.
Directory-linked investors include Andreessen Horowitz (/fund/andreessen-horowitz), Altimeter Capital (/fund/altimeter-capital), Tiger Global Management (/fund/tiger-global-management), and Sequoia (/fund/sequoia).
Benchling raised a $100M Series F in November 2021 at a reported $6.1B valuation — a late-stage private growth company.
Biotech R&D still runs on spreadsheets and paper notebooks. Benchling became the category-defining SaaS system of record — the 'Salesforce for lab science' — enabling reproducibility and collaboration at scale.
No — Benchling remains a private company as of July 2026.
Last updated: 2026-07-24